MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
16.50
+0.38
+2.36%
After Hours: 16.50 0 0.00% 19:52 12/18 EST
OPEN
16.53
PREV CLOSE
16.12
HIGH
16.99
LOW
16.46
VOLUME
2.87M
TURNOVER
--
52 WEEK HIGH
20.76
52 WEEK LOW
5.81
MARKET CAP
2.52B
P/E (TTM)
-30.6634
1D
5D
1M
3M
1Y
5Y
1D
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT), Novan (NOVN) and Adaptive Biotechnologies (ADPT)
TipRanks · 2d ago
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer Collaborations and Surging 2024 Share Price
Simply Wall St · 2d ago
Adaptive Biotechnologies (ADPT) Receives a Buy from J.P. Morgan
TipRanks · 2d ago
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst
Benzinga · 3d ago
Adaptive Biotechnologies: Strategic Collaborations and Growth Potential Drive Buy Rating
TipRanks · 3d ago
Adaptive Biotechnologies Signs Two Immune Receptor Licensing Agreements with Pfizer
Reuters · 3d ago
ADAPTIVE BIOTECHNOLOGIES CORP: SPECIFIC FINANCIAL TERMS OF AGREEMENT WILL NOT BE DISCLOSED
Reuters · 3d ago
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.